Summary:
NeoGenomics has launched PanTracer Tissue and PanTracer Tissue + HRD, advanced solid tumor profiling assays designed to deliver faster, comprehensive genomic insights, including critical biomarkers for therapy selection and clinical trials.

Takeaways:

  1. Broad Genomic Coverage: The solution analyzes over 500 cancer-related genes and meets clinical guideline recommendations.
  2. HRD Integration: It also can have added + HRD testing, which includes BRCA status and genomic instability scoring, aiding ovarian cancer treatment decisions.
  3. Faster Results: Results may be delivered in as little as 8 days, helping clinicians quickly initiate personalized treatment plans.

NeoGenomics, Inc., a provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confidently.

PanTracer Tissue evaluates over 500 cancer-related genes and aligns with clinical guidelines, covering key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment. Results may be delivered in as little as 8 days, enabling physicians to rapidly initiate treatment strategies. Minimal specimen requirements make it suitable for a wide range of tumor types and practice settings. The assay builds on the company’s tissue-based CGP platform, previously known as NeoComprehensive Solid Tumor.

The addition of PanTracer Tissue + HRD offers enhanced tumor profiling by incorporating homologous recombination deficiency analysis into a single, guideline-aligned test for ovarian cancer. The PanTracer Tissue + HRD offering includes BRCA mutation status and a genomic instability score—critical biomarkers that can help guide the use of PARP inhibitors and other therapies targeting DNA repair pathways. The combined approach streamlines ordering and can shorten time to actionable results by capturing a broader range of clinically relevant genomic alterations, gene fusions, and DNA repair deficiencies.

“With PanTracer Tissue and PanTracer Tissue + HRD we’re unlocking a more complete genomic view from a single sample, giving physicians clearer answers, sooner,” says Warren Stone, president and chief operating officer at NeoGenomics. “With the addition of PanTracer Tissue + HRD, we are expanding our portfolio to address the unmet need for ovarian cancer therapy selection with the objective of improving patient care.”

Part of a Broader Portfolio

PanTracer Tissue and PanTracer Tissue + HRD are part of NeoGenomics’ broader portfolio of precision oncology solutions designed to improve patient outcomes through high-quality, guideline-aligned testing. Revealed at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the continually expanding PanTracer portfolio reflects the company’s dedicated focus on advancing diagnostic tools that support more informed, personalized care.

Featured Image: PanTracer Tissue is a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). Image: NeoGenomics